Figure 6

MMP9 and MUC4 protein serum levels determined by ELISA immunoassays. Scatter graphs showing two forms of MMP9 (active form and pro-form) (A), MMP9 bound to TIMP1 (B), and MUC4 (C) individual concentration values (with means) of non-glioma (CTRL: controls), glioma grade (III), and glioblastoma (GBM) patients. N = 10 for each group (30 patients in total). MMP9 protein levels (ng/ml) and MUC4 protein levels (ng/ml) measured in serum, were normalized based on the total protein; results are given as ng/ml per mg/ml of total protein. The different forms of MMP9 measured in each assay are represented in (A) and (B), and MUC4 structure and cleavage site is represented in (C). Bars represent protein mean levels. MMP9 two forms protein levels as well as the MMP9:TIMP1 complex are significantly higher in the GBM than in grade III group (Tukey’s multiple comparison test, p = 0.022 and 0.018, respectively). MUC4 values are represented on a stretched Y axis in (C). Higher concentrations of MUC4 are found in malignant glioma grades compared with controls but the difference does not reach significance. NIDO Nidogen-like domain, AMOP Adhesion-associated domain, and VWD Von Willbrand factor domain.